Molenzavir(Molnupiravir)
Therapeutic Group: Anti Viral
Presentation
Molenzavir 200 Capsule: Each capsule contains Molnupiravir INN 200 mg.
Description
Molnupiravir is an investigational antiviral drug, which is the prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits the replication of multiple RNA viruses, including
SARS-CoV-2. It has broad spectrum antiviral activity against influenza virus and coronaviruses, such as MERS-CoV, and SARS-CoV. It is aimed at the treatment of COVID-19 in-
• patients hospitalized due to mild, moderate or severe disease,
• non-hospitalized patients with mild or moderate disease.
Indications
Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Dosage & Administration
* 800 mg (4 capsules), Twice daily, 5 days, Orally
The safety & efficacy of Molnupiravir in patients below 18 years of age have not been established. No dosage adjustment is required for renal, hepatic impairment & elderly
patients.
Side Effects
Common adverse reactions are diarrhoea, nausea, dizziness, headache, rash and urticaria etc
Precautions
N/A
Use in Pregnancy & Lactation
There are no data from the use of Molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity. It is not recommended during pregnancy.
It is unknown whether Molnupiravir or any of the components of Molnupiravir is present in human milk, affects human milk production, or has effect on the breastfed infant.
Drug Interaction
No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with molnupiravir
Storage
Do not store above 30 â°C. Keep away from light and out of the reach of children.
Commercial Pack
Molenzavir 200: Each box contains 5 Alu-Alu blister strips of 4 capsules.